Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and Chairman of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.
He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). He previously served on the board of Thrive Earlier Detection, which was acquired by Exact Sciences (NASDAQ: EXACT) in January, 2021. Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Since the early days of the pandemic, Mike has also been serving as a Senior Advisor to the Rockefeller Foundation’s efforts on COVID-19 testing. (https://www.rockefellerfoundation.org/report/a-resetting-of-americas-response-to-covid-19/)
Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.